Zepbound
FDA approves Eli Lilly’s diabetes drug Mounjaro for obesity with a new name :Zepbound
The US Food and Drug Administration (FDA) approved a new drug called Zepbound for weight loss. Zepbound is a newer and more effective weight loss drug than other approved drugs. It is taken as a shot once a week and is used in addition to a reduced calorie diet and increased exercise.
Zepbound is made by Eli Lilly and is part of a new class of drugs called GLP-1 receptor agonists. These drugs work by mimicking hormones that stimulate the release of insulin, increase feelings of fullness, and reduce appetite.
Zepbound is expected to cost about $1,060 per month before insurance. Eli Lilly is offering a savings card for patients with commercial insurance to be able to get the drug for $25 for a one- or three-month prescription, if patients’ plans cover the medicine.
Zepbound is still listed on the FDA’s drug shortages list, but both Lilly and Novo Nordisk have been investing heavily in increasing manufacturing of the medicines as their use has soared.
Key points:
- New weight loss drug called Zepbound approved by FDA
- Zepbound is more effective than other approved drugs
- Taken as a shot once a week in addition to diet and exercise
- Made by Eli Lilly and part of a new class of drugs
- Expected to cost about $1,060 per month before insurance
- Savings card available for patients with commercial insurance
- Still listed on FDA drug shortages list, but Lilly and Novo Nordisk are increasing manufacturing
- side effects of this drug : are gastrointestinal issues like nausea,
- vomiting, constipation and diarrhea
- the FDA said. The drug’s label will contain warnings for inflammation of the pancreas, gallbladder problems, low blood sugar, acute kidney injury, diabetic retinopathy, or damage to the eye’s retina, in patients with type 2 diabetes mellitus and suicidal behavior or thinking.
